GlaxoSmithKline Management Discusses Q2 2012 Results - Earnings Call Transcript

GlaxoSmithKline (GSK)

Q2 2012 Earnings Call

July 25, 2012 8:15 am ET

Executives

Compare to:
Previous Statements by GSK
» GlaxoSmithKline's CEO Discusses Q1 2012 Results - Earnings Call Transcript
» GlaxoSmithKline plc's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» GlaxoSmithKline plc's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Andrew Philip Witty - Chief Executive Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee

Simon Dingemans - Chief Financial Officer, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee

Moncef Slaoui - Chairman of Research & Development, Executive Director, Member of Corporate Administration & Transactions Committee and Member of Finance Committee

Analysts

Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

Graham Parry - BofA Merrill Lynch, Research Division

Andrew S. Baum - Citigroup Inc, Research Division

Alexandra Hauber - JP Morgan Chase & Co, Research Division

Gbola Amusa - UBS Investment Bank, Research Division

Jo Walton - Crédit Suisse AG, Research Division

Brian Bourdot - Barclays Capital, Research Division

Presentation

Andrew Philip Witty

Good afternoon, and thank you very much for joining me by link today. I'm sorry we're not doing this face-to-face. But I'm sure you'll understand, we're trying to avoid everybody being caught up in Olympic lane. And hopefully, this works for you in terms of avoiding being trapped in traffic.

We're going to review the Q2 results for GSK. And with me today, I've got Simon Dingemans, our CFO, who'll make some comments in a few minutes. And also, Moncef Slaoui, who will join Simon and I for question-and-answer at the end, so you'll have an opportunity to ask about pipeline assets, if you'd like.

Let me start by making a few general comments about the quarter. It's been an interesting quarter for the company, a very busy one, really a couple of big dynamics. The first is some very, very good progression of the advanced pipeline. We'll talk a little bit more about that. But clearly, during the quarter, we've seen a lot of very encouraging data, particularly around some of the bigger potential assets in the pipeline. While there still so much to do to bring those assets to the marketplace, it's clearly coming into shape as a potential driver of enhanced organic growth going forward.

1 2 3 4 Next › Last »